Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 4/20 | 0.34 |
| ▸ | PDE4A | P27815 | 4/20 | 0.34 |
| ▸ | PDE4B | Q07343 | 4/20 | 0.34 |
| ▸ | PDE4C | Q08493 | 4/20 | 0.34 |
| ▸ | PDE4D | Q08499 | 4/20 | 0.34 |
| ▸ | HTR1F | P30939 | 4/20 | 0.34 |
| ▸ | HTR1A | P08908 | 3/20 | 0.34 |
| ▸ | HTR1D | P28221 | 3/20 | 0.34 |
| ▸ | HTR1B | P28222 | 2/20 | 0.34 |
| ▸ | GLS | O94925 | 1/20 | 0.33 |
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.33 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.33 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.33 |
| ▸ | CDK2 | P24941 | 1/20 | 0.33 |
| ▸ | PDE5A | O76074 | 1/20 | 0.33 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.32 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16146367 | 0.81 | GDA (0.46) | GDACDK2ADORA3 | |
| SCHEMBL16146600 | 0.76 | TSHR (0.46) | CHRM3PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL16146526 | 0.75 | ADORA3 (0.43) | GDAADORA3 | |
| SCHEMBL9021288 | 0.75 | CYP1A2 (0.40) | CYP2C9HTR1FHTR1AHTR1DHTR1B | |
| SCHEMBL16146678 | 0.75 | GDA (0.39) | GDAADORA3 | |
| SCHEMBL16146754 | 0.75 | GDA (0.39) | GDAADORA3ABL1 | |
| SCHEMBL16145714 | 0.74 | GDA (0.38) | GDAADORA3 | |
| SCHEMBL16146723 | 0.74 | GDA (0.38) | GDAADORA3 | |
| SCHEMBL14196063 | 0.74 | XDH (0.40) | GDA | |
| SCHEMBL16146641 | 0.74 | GDA (0.38) | GDA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140303112-A1 | Method for treating disease or condition susceptible to amelioration by AMPK activators and compounds of formula which are useful to activate AMP-activated protein kinase (AMPK) | ENERGENESIS BIOMEDICAL CO., LTD (TW) | 2014-10-09 | — | — | US | claimed |
| US-9938279-B2 | Method for treating disease or condition susceptible to amelioration by AMPK activators and compounds of formula which are useful to activate AMP-activated protein kinase (AMPK) | ENERGENESIS BIOMEDICAL CO., LTD (TW) | 2018-04-10 | — | — | US | disclosed |
| US-20140303112-A1 | Method for treating disease or condition susceptible to amelioration by AMPK activators and compounds of formula which are useful to activate AMP-activated protein kinase (AMPK) | ENERGENESIS BIOMEDICAL CO., LTD (TW) | 2014-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140303112-A1 | Method for treating disease or condition susceptible to amelioration by AMPK activators and compounds of formula which are useful to activate AMP-activated protein kinase (AMPK) | PRKAG2, PRKAB2, PRKAG1 | CYP2D6 4390/4885CYP2C9 4597/4885CHRM3 1371/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.